Anzeige
Meldung des Tages: 9 von 13 Treffern in den ersten 25 Metern: Wird das der Gamechanger für diese Goldaktie?
Werbung
Attraktive Knock-Outs auf AbbVie Inc
Typ Hebel Bid / Ask WKN
Call
4,8 3,78 € / 3,86 €
SX7T95
Typ Hebel Bid / Ask WKN
Put
4,8 3,78 € / 3,86 €
SX14P0
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf AbbVie Inc

AbbVie Aktie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
182,40 €
-0,80 €
-0,44%
09:30:18 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
6,56 $
Dividendenrendite
3,38%
neu: Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 7,42: VG75H6
Werbung

AbbVie News

25.04.25 - PR Newswire
AbbVie Reports First-Quarter 2025 Financial Results
AbbVie Reports First-​Quarter 2025 Financial Results PR Newswire
25.04.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire
25.04.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Fokus: Bayer, Continental, Steel Dynamics, AbbVie und Schlumberger
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
24.04.25 - PR Newswire
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines PR Newswire
24.04.25 - PR Newswire
The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV
The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV PR Newswire
22.04.25 - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders PR Newswire
21.04.25 - PR Newswire
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV PR Newswire
18.04.25 - PR Newswire
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire
17.04.25 - PR Newswire
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire
08.04.25 - Aktienwelt360
Finanzielle Freiheit mit Dividenden? Nimm einfach diese 2 Aktien als Einkommens-Booster!
Bist du auch schon mal belächelt worden, wenn du anderen erzählt hast, dir mit Dividenden eine gewisse finanzielle Unabhängigkeit aufbauen zu wollen? Nimm es diesen Leuten ...
08.04.25 - PR Newswire
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis PR Newswire
31.03.25 - PR Newswire
AbbVie to Host First-Quarter 2025 Earnings Conference Call
AbbVie to Host First-​Quarter 2025 Earnings Conference Call PR Newswire
26.03.25 - PR Newswire
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 PR Newswire
26.03.25 - LYNX Analysen
AbbVie mit Kursrückgang – was könnte dahinterstecken?
Der US-​amerikanische Biotechnologie- und Pharmakonzern zeigte sich in den letzten Wochen von seiner positiven Seite. Während es an der Wall Street überaus turbulent zuging, ...
24.03.25 - PR Newswire
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 PR Newswire
15.03.25 - PR Newswire
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
ELAHERE® (mirvetuximab soravtansine-​gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients PR Newswire
04.03.25 - PR Newswire
AbbVie to Present at the Leerink Partners Global Healthcare Conference
AbbVie to Present at the Leerink Partners Global Healthcare Conference PR Newswire
03.03.25 - PR Newswire
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity PR Newswire
28.02.25 - PR Newswire
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis PR Newswire
26.02.25 - PR Newswire
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference PR Newswire

Newssuche

Videos

newspaper
27.01.26 +1,29%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »